Doctor Frank Kramer
Institute for Target Discovery / Biomarker, Bayer Schering Pharma AG, Wuppertal (Germany)
Evaluation of high sensitivity C-reactive protein in vericiguat-treated patients with heart failure with reduced ejection fraction
Event: Heart Failure 2018
Topic: Pharmacotherapy
Session: Chronic Heart Failure – Treatment
ESC 365 is supported by
